Marker Therapeutics, Inc.

Monthly Archives: January 2015

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers January 12, 2015, Seattle WA, TapImmune Inc.
Read More

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

...Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each “unit” consisting of one share of common stock and one of each of the following warrants: Series A warrants to purchase up to an aggregate of 7,320,000 shares of common stock with an exercise price of $1.50 per share (such exercise price subject to full price protection for dilutive issuances) and a term of five years;
Read More